Cencora, Inc. $COR Shares Sold by Lbp Am Sa

Key Points

• Lbp Am Sa reduced its stake in Cencora by 23.6% in Q4, selling 24,798 shares and retaining 80,106 shares valued at about $27.06 million.
• Several large funds notably increased positions (Marshall Wace +518.9%, UBS +528.9%, Mizuho +116.4%, Vanguard +4.1%), and institutional investors now own 97.52% of Cencora's stock.
• Cencora reported EPS of $4.08 (beating the $4.04 estimate) with revenue slightly below expectations, has a market cap of $61.71B, pays a $0.60 quarterly dividend (0.8% yield), and carries a consensus analyst rating of Moderate Buy with an average target of $398.17.

Lbp Am Sa lessened its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 23.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 80,106 shares of the company's stock after selling 24,798 shares during the period. Lbp Am Sa's holdings in Cencora were worth $27,056,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of COR. Marshall Wace LLP raised its position in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company's stock worth $623,534,000 after purchasing an additional 1,672,762 shares during the last quarter. Mizuho Markets Americas LLC grew its stake in Cencora by 116.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company's stock valued at $66,506,000 after acquiring an additional 1,511,906 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company's stock valued at $461,250,000 after acquiring an additional 1,241,186 shares in the last quarter. Viking Global Investors LP grew its stake in Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company's stock valued at $624,207,000 after acquiring an additional 1,013,913 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Cencora by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company's stock valued at $7,311,810,000 after acquiring an additional 916,506 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

Cencora stock opened at $317.22 on Thursday. The firm has a 50 day simple moving average of $343.36 and a 200-day simple moving average of $342.88. Cencora, Inc. has a 1-year low of $271.00 and a 1-year high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The stock has a market cap of $61.71 billion, a price-to-earnings ratio of 38.13, a price-to-earnings-growth ratio of 1.49 and a beta of 0.72.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion during the quarter, compared to analysts' expectations of $86.12 billion. During the same quarter in the prior year, the company posted $3.73 EPS. The business's revenue for the quarter was up 5.5% on a year-over-year basis. On average, analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, February 13th. Cencora's dividend payout ratio is currently 28.85%.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the company's stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.38% of the company's stock.

Wall Street Analyst Weigh In

COR has been the subject of several research reports. Robert W. Baird set a $415.00 price objective on shares of Cencora in a research note on Tuesday, January 13th. Leerink Partners reaffirmed an "outperform" rating on shares of Cencora in a research note on Tuesday, March 17th. Barclays upped their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an "overweight" rating in a research note on Friday, February 13th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. Finally, Weiss Ratings raised shares of Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research note on Thursday, February 5th. Twelve investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and an average price target of $398.17.

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.